Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Augusta University
Novartis
Novartis
Novartis
M.D. Anderson Cancer Center
Novartis
Novartis